TSPO and myeloid sarcoma: The aim of this study was, therefore, to establish the applicability of the third-generation TSPO ligand, (18F)-GE180, to (semi-)quantify glia cell activation and neuroinflammation in a MS mouse model, and to directly correlate ligand binding with TSPO expression.